These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 31792256

  • 1. Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients.
    Schiza A, Irenaeus S, Ortiz-Nieto F, Loskog A, Tötterman T, Sundin A, Ullenhag GJ, Ahlström H.
    Sci Rep; 2019 Dec 02; 9(1):18069. PubMed ID: 31792256
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
    Zimmermann C, Distler M, Jentsch C, Blum S, Folprecht G, Zöphel K, Polster H, Troost EGC, Abolmaali N, Weitz J, Baumann M, Saeger HD, Grützmann R.
    Strahlenther Onkol; 2021 Jan 02; 197(1):19-26. PubMed ID: 32638040
    [Abstract] [Full Text] [Related]

  • 3. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
    Schmidt S, Dunet V, Koehli M, Montemurro M, Meuli R, Prior JO.
    Acta Radiol; 2013 Oct 02; 54(8):837-42. PubMed ID: 23761549
    [Abstract] [Full Text] [Related]

  • 4. Clinical and Prognostic Value of 18F-FDG-PET/CT in the Restaging Process of Recurrent Cutaneous Melanoma.
    Albano D, Familiari D, Fornito MC, Scalisi S, Laudicella R, Galia M, Grassedonio E, Ruggeri A, Ganduscio G, Messina M, Spada M, Midiri M, Alongi P.
    Curr Radiopharm; 2020 Oct 02; 13(1):42-47. PubMed ID: 31595860
    [Abstract] [Full Text] [Related]

  • 5. Preliminary comparison of diffusion-weighted MRI and PET/CT in predicting histological type and malignancy of lung cancer.
    Liu LP, Zhang XX, Cui LB, Li J, Yang JL, Yang HN, Zhang Y, Zhou Y, Tang X, Qi S, Fang Y, Zhang J, Yin H.
    Clin Respir J; 2017 Mar 02; 11(2):151-158. PubMed ID: 25918835
    [Abstract] [Full Text] [Related]

  • 6. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer.
    Goense L, Heethuis SE, van Rossum PSN, Voncken FEM, Lagendijk JJW, Lam MGEH, Terhaard CH, van Hillegersberg R, Ruurda JP, Mook S, van Lier ALHMW, Lin SH, Meijer GJ.
    Nucl Med Commun; 2018 Jan 02; 39(1):60-67. PubMed ID: 29023336
    [Abstract] [Full Text] [Related]

  • 7. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.
    Karan B, Pourbagher A, Torun N.
    J Magn Reson Imaging; 2016 Jun 02; 43(6):1434-44. PubMed ID: 26663655
    [Abstract] [Full Text] [Related]

  • 8. 18F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma.
    Eschbach RS, Kazmierczak PM, Heimer MM, Todica A, Hirner-Eppeneder H, Schneider MJ, Keinrath G, Solyanik O, Olivier J, Kunz WG, Reiser MF, Bartenstein P, Ricke J, Cyran CC.
    Cancer Imaging; 2018 Jan 18; 18(1):2. PubMed ID: 29347968
    [Abstract] [Full Text] [Related]

  • 9. The utility of ADC value in diffusion-weighted whole-body MRI in the follow-up of patients with multiple myeloma. Correlation study with 18F-FDG PET-CT.
    Paternain A, García-Velloso MJ, Rosales JJ, Ezponda A, Soriano I, Elorz M, Rodríguez-Otero P, Aquerreta JD.
    Eur J Radiol; 2020 Dec 18; 133():109403. PubMed ID: 33202373
    [Abstract] [Full Text] [Related]

  • 10. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging.
    Azad GK, Taylor BP, Green A, Sandri I, Swampillai A, Harries M, Kristeleit H, Mansi J, Goh V, Cook GJR.
    Eur J Nucl Med Mol Imaging; 2019 Apr 18; 46(4):821-830. PubMed ID: 30506455
    [Abstract] [Full Text] [Related]

  • 11. Prediction of survival with combining quantitative 18 F-FDG PET/CT and DW-MRI parameters in sinonasal malignancies.
    Ozturk K, Gencturk M, Caicedo-Granados E, Li F, Cayci Z.
    Head Neck; 2019 Sep 18; 41(9):3080-3089. PubMed ID: 31041831
    [Abstract] [Full Text] [Related]

  • 12. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F, Wassberg C, Selling J, Molin D, Ahlström H.
    Clin Radiol; 2015 Nov 18; 70(11):1229-36. PubMed ID: 26208992
    [Abstract] [Full Text] [Related]

  • 13. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo18F-FDG-PET.
    Schwenck J, Schörg B, Fiz F, Sonanini D, Forschner A, Eigentler T, Weide B, Martella M, Gonzalez-Menendez I, Campi C, Sambuceti G, Seith F, Quintanilla-Martinez L, Garbe C, Pfannenberg C, Röcken M, la Fougere C, Pichler BJ, Kneilling M.
    Theranostics; 2020 Nov 18; 10(2):925-937. PubMed ID: 31903160
    [Abstract] [Full Text] [Related]

  • 14. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using 18F-FDG PET/CT and DW-MRI: A Prospective Multicenter Study.
    Borggreve AS, Goense L, van Rossum PSN, Heethuis SE, van Hillegersberg R, Lagendijk JJW, Lam MGEH, van Lier ALHMW, Mook S, Ruurda JP, van Vulpen M, Voncken FEM, Aleman BMP, Bartels-Rutten A, Ma J, Fang P, Musall BC, Lin SH, Meijer GJ.
    Int J Radiat Oncol Biol Phys; 2020 Apr 01; 106(5):998-1009. PubMed ID: 31987972
    [Abstract] [Full Text] [Related]

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Apr 01; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 16. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
    Albano D, Patti C, Matranga D, Lagalla R, Midiri M, Galia M.
    Eur J Radiol; 2018 Jun 01; 103():90-98. PubMed ID: 29803392
    [Abstract] [Full Text] [Related]

  • 17. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
    Rakheja R, Chandarana H, DeMello L, Jackson K, Geppert C, Faul D, Glielmi C, Friedman KP.
    AJR Am J Roentgenol; 2013 Nov 01; 201(5):1115-9. PubMed ID: 24147485
    [Abstract] [Full Text] [Related]

  • 18. Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and (18)F-FDG PET.
    Iizuka Y, Matsuo Y, Umeoka S, Nakamoto Y, Ueki N, Mizowaki T, Togashi K, Hiraoka M.
    Eur J Radiol; 2014 Nov 01; 83(11):2087-92. PubMed ID: 25174774
    [Abstract] [Full Text] [Related]

  • 19. Correlation of mean apparent diffusion coefficient (ADC) and maximal standard uptake value (SUVmax) evaluated by diffusion-weighted MRI and 18F-FDG-PET/CT in children with Hodgkin lymphoma: a feasibility study.
    Rosbach N, Fischer S, Koch V, Vogl TJ, Bochennek K, Lehrnbecher T, Mahmoudi S, Grünewald L, Grünwald F, Bernatz S.
    Radiol Oncol; 2023 Jun 01; 57(2):150-157. PubMed ID: 37341195
    [Abstract] [Full Text] [Related]

  • 20. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma.
    Sakane M, Tatsumi M, Kim T, Hori M, Onishi H, Nakamoto A, Eguchi H, Nagano H, Wakasa K, Hatazawa J, Tomiyama N.
    Acta Radiol; 2015 Sep 01; 56(9):1034-41. PubMed ID: 25267921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.